Cited by 1,124Diabetes Treatment and ManagementPeptidase Inhibition and AnalysisPancreatic function and diabetes

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T J, McIntosh, C H, Pederson, R A·1995·Endocrinology

Open this paper in CoChat — free account

Abstract

The combined actions of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) may fully account for the incretin effect. These hormones are released from the small intestine in response to oral glucose and stimulate insulin release. Recently, evidence has been provided demonstrating the degradation of GIP-(1-42) and GLP-1-(7-36)NH2 by the serum enzyme dipeptidyl peptidase IV (DPP IV) into the biologically inactive products GIP-(3-42) and GLP-1-(9-36)NH2. The objective of the current investigation was to develop a method to monitor the degradation of these hormones in vivo. Synthetic peptides were radiolabeled and purified by HPLC. Subsequent degradation of the peptides under various conditions was then monitored by further HPLC analysis. Incubation of [125I]GIP-(1-42) or [125I]GLP-1-(7-36)NH2 with Wistar rat serum or purified DPP IV resulted in the major N-terminal-truncated products [125I]GIP-(3-42) and [125I]GLP-1-(9-36)NH2. These products were significantly reduced when the specific DPP IV inhibitor diprotin A was included in the incubation mixture and were absent when serum from DPP IV-deficient rats was used. When the labeled peptides were infused into rats at hormone levels within the physiological range, over 50% was metabolized to the truncated forms within 2 min. These products were absent when the tracers were infused into DPP IV-deficient animals. It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo. As the N-terminal-truncated products of the DPP IV cleavage may not be distinguished from the biologically active hormone by currently employed assays, reports of circulating hormone levels should be reconsidered. The method described in this manuscript may be useful for investigating the durations of action of GIP and tGLP-1 in normal and pathophysiological conditions.

Integrity signals

Registry

Crossref · 10.1210/endo.136.8.7628397

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 591
Proline-Dependent Structural and Biological Properties of Peptides and Proteins
Yaron, A., Naider, F. R., & Scharpé, S. (1993) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239309082572 · Cited by 551
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamide
Hopsu-Havu, V. K., & Glenner, G. G. (1966) · Histochemistry and Cell Biology · doi:10.1007/bf00577838 · Cited by 437
Entero-Insular Axis
Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371

Show all 36 references

Sorted by citations

Items 101–200 of 997

Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening
Koole, C., Wootten, D. L., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 225
Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
Ban, K., Kim, K.-H., Cho, C.-K., Sauvé, M., Diamandis, E. P., Backx, P. H., Drucker, D. J., & Husain, M. (2010) · Endocrinology · doi:10.1210/en.2009-1197 · Cited by 232
Glucagon-Like Peptide 1 Secretion by the L-Cell
Lim, G. E., & Brubaker, P. L. (2006) · Diabetes · doi:10.2337/db06-s020 · Cited by 220
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides
Zhu, L., Tamvakopoulos, C., Xie, D., Dragovic, J., Shen, X., Fenyk-Melody, J. E., Schmidt, K. T., Bagchi, A., Griffin, P. R., Thornberry, N. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212355200 · Cited by 221
Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2
Brubaker, P. L., & Anini, Y. (2003) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y03-107 · Cited by 223
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 213
Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats
Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Self-citation
Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate
Kim, J., Baggio, L. L., Bridon, D. P., Castaigne, J., Robitaille, M. F., Jetté, L., Benquet, C., & Drucker, D. J. (2003) · Diabetes · doi:10.2337/diabetes.52.3.751 · Cited by 209
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release and Actions
Ballantyne, G. H. (2006) · Obesity Surgery · doi:10.1381/096089206776944959 · Cited by 212
Preproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Abu‐Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1296 · Cited by 203
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
On the origin of serum CD26 and its altered concentration in cancer patients
Cordero, O. J., Salgado, F. J., & Nogueira, M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0728-1 · Cited by 203
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo
Fujita, Y., Wideman, R. D., Speck, M., Asadi, A., King, D., Webber, T. D., Haneda, M., & Kieffer, T. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90636.2008 · Cited by 199
Self-citation
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice
Reimer, M. K., Holst, J. J., & Åhrén, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 196
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A., & Meester, I. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00387 · Cited by 194
Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Deacon, C. F., Åhrén, B., & Holst, J. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1091 · Cited by 193
Passing the baton in class B GPCRs: peptide hormone activation via helix induction?
Parthier, C., Reedtz‐Runge, S., Rudolph, R., & Stubbs, M. T. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.02.004 · Cited by 193
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
Åhrén, B., Holst, J. J., Mårtensson, H., & Balkan, B. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00600-2 · Cited by 193
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh, C. H. S., Demuth, H., Pospisilik, J. A., & Pederson, R. A. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.001 · Cited by 192
Self-citation
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
Smith, N. K., Hackett, T. A., Galli, A., & Flynn, C. R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.010 · Cited by 204
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
Havale, S. H., & Pal, M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.061 · Cited by 190
Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation
Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 202
DPP4 in Cardiometabolic Disease
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 190
Glucagon-like peptide 1 and appetite
Dailey, M. J., & Moran, T. H. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.11.008 · Cited by 200
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Hansotia, T., & Drucker, D. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 187
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 192
Effects of GLP-1-(7–36)NH2, GLP-1-(7–37), and GLP-1- (9–36)NH2on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 176
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
Plamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1847-7 · Cited by 173
Bowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 172
Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 173
Self-citation
Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans
Åhrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., & Foley, J. E. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01414.x · Cited by 171
High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor
Montrose‐Rafizadeh, C., Yang, H. M., Rodgers, B. D., Beday, A., Pritchette, L. A., & Eng, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21201 · Cited by 171
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166
Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats
Sudre, B., Broqua, P., White, R. B., Ashworth, D. M., Evans, D. M., Haigh, R. M., Junien, J., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165
Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice
Flock, G. B., Baggio, L. L., Longuet, C., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0697 · Cited by 164
Regulation of Na+/H+exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells
Carraro‐Lacroix, L. R., Malnic, G., & Girardi, A. C. C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00082.2009 · Cited by 163
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01362.x · Cited by 161
Osteocalcin Induces Release of Glucagon-Like Peptide-1 and Thereby Stimulates Insulin Secretion in Mice
Mizokami, A., Yasutake, Y., Gao, J., Matsuda, M., Takahashi, I., Takeuchi, H., & Hirata, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057375 · Cited by 160
Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis
Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S. (2007) · Diabetes · doi:10.2337/db06-1182 · Cited by 158
Oral delivery of therapeutic protein/peptide for diabetes – Future perspectives
Rekha, M. R., & Sharma, C. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.056 · Cited by 155
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Yoshida, T., Akahoshi, F., Sakashita, H., Kitajima, H., Nakamura, M., Sonda, S., Takeuchi, M., Tanaka, Y., Ueda, N., Sekiguchi, S., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.012 · Cited by 159
Molecular mechanisms underlying nutrient-stimulated incretin secretion
Parker, H. E., Reimann, F., & Gribble, F. M. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940900132x · Cited by 155
Investigation of Glucose-dependent Insulinotropic Polypeptide(1-42) and Glucagon-like Peptide-1-(7-36) Degradation by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry
Pauly, R. P., Rosche, F., Wermann, M., McIntosh, C. H. S., Pederson, R. A., & Demuth, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23222 · Cited by 155
Self-citation
Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
Real-time trafficking and signaling of the glucagon-like peptide-1 receptor
Roed, S. N., Wismann, P., Underwood, C. R., Kulahin, N., Iversen, H., Cappelen, K. A., Schäffer, L., Lehtonen, J., Hecksher-Soerensen, J., Secher, A., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.11.010 · Cited by 153
Blood-Brain Barriers in Obesity
Rhea, E. M., Salameh, T. S., Logsdon, A. F., Hanson, A. J., Erickson, M. A., & Banks, W. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0079-3 · Cited by 166
Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 150
Liraglutide and obesity: a review of the data so far
Ladenheim, E. E. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 147
Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism
Grunddal, K. V., Ratner, C., Svendsen, B., Sommer, F., Engelstoft, M. S., Madsen, A. N., Pedersen, J., Nøhr, M. K., Egerod, K. L., Nawrocki, A. R., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1600 · Cited by 147
Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs
Deacon, C. F., Danielsen, P. L., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 146
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 144
Self-citation
Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 149
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
Mest, H. ‐., & Mentlein, R. (2005) · Diabetologia · doi:10.1007/s00125-005-1707-5 · Cited by 141
Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat
Pospisilik, J. A., Stafford, S. G., Demuth, H., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 138
Self-citation
The Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 138
Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2
Brubaker, P. L., Crivici, A., Izzo, A. A., Ehrlich, P. F., Tsai, C.-H., & Drucker, D. J. (1997) · Endocrinology · doi:10.1210/endo.138.11.5482 · Cited by 136
Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin
Gault, V. A., O'Harte, F. P. M., Harriott, P., Mooney, M., Green, B., & Flatt, P. R. (2003) · Diabetologia · doi:10.1007/s00125-002-1028-x · Cited by 134
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.004 · Cited by 132
Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus
Holz, G. G., & Chepurny, O. G. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 134
Dipeptidyl Peptidase IV-Resistant [ d -Ala2]Glucose-Dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats
Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H., & McIntosh, C. H. S. (2002) · Diabetes · doi:10.2337/diabetes.51.3.652 · Cited by 133
Self-citation
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
Meier, J. J., Gallwitz, B., Schmidt, W. E., & Nauck, M. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01434-6 · Cited by 133
Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice
Gunnarsson, P. T., Winzell, M. S., Deacon, C. F., Larsen, M. O., Jelic, K., Carr, R. D., & Åhrén, B. (2006) · Endocrinology · doi:10.1210/en.2005-1442 · Cited by 130
Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00870.2004 · Cited by 131
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
Neuropeptide Y, B‐type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein‐α
Keane, F. M., Nadvi, N. A., Yao, T., & Gorrell, M. D. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08051.x · Cited by 129
Glucagon-Like Peptide 1 Interacts with Ghrelin and Leptin to Regulate Glucose Metabolism and Food Intake through Vagal Afferent Neuron Signaling ,
Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Dunning, B. E., Mangold, B. L. K., Mone, M. D., Russell, M. E., Weldon, S. C., & Hughes, T. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025522z · Cited by 122
Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon
Hinke, S. A., Pospisilik, J. A., Demuth, H.-U., Manhart, S., Kühn‐Wache, K., Hoffmann, T., Nishimura, E., Pederson, R. A., & McIntosh, C. H. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3827 · Cited by 122
Self-citation
Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
Barrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120
Renal effects of glucagon-like peptide in rats
Moreno, C., Mistry, M., & Roman, R. J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01542-4 · Cited by 121
Glucagon-like peptide 2 function in domestic animals
Burrin, D. G., Stoll, B., & Guan, X. (2003) · Domestic Animal Endocrinology · doi:10.1016/s0739-7240(02)00210-2 · Cited by 127
Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
Katsurada, K., & Yada, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12464 · Cited by 126
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 129
Fish skin gelatin hydrolysates as dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 stimulators improve glycaemic control in diabetic rats: A comparison between warm- and cold-water fish
Wang, T.-Y., Hsieh, C., Hung, C.-C., Jao, C., Chen, M., & Hsu, K. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.09.037 · Cited by 118
High fat diet induces microbiota-dependent silencing of enteroendocrine cells
Ye, L., Mueller, O., Bagwell, J., Bagnat, M., Liddle, R. A., & Rawls, J. F. (2019) · eLife · doi:10.7554/elife.48479 · Cited by 120
Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats
Tavares, W., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.1.e134 · Cited by 118
Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase
Poplawski, S. E., Lai, J. H.-S., Li, Y., Jin, Z., Liu, Y., Wu, W., Wu, Y. H., Zhou, Y., Sudmeier, J. L., Sanford, D. G., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400351a · Cited by 117
Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes
Deacon, C. F., & Holst, J. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.011 · Cited by 117
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
Green, B. D., Irwin, N., Duffy, N. A., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.043 · Cited by 116
Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents
Ahn, J. H., Kim, H.-M., Jung, S. H., Kang, S. K., Kim, K. R., Rhee, S. D., Yang, S., Cheon, H. G., & Kim, S. S. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.06.046 · Cited by 116
Cell-Surface Peptidases
Mentlein, R. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)35004-7 · Cited by 115
Glucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation
Lee, Y.-S., Lee, C., Choung, J.-S., Jung, H.-S., & Jun, H.-S. (2018) · Diabetes · doi:10.2337/db18-0155 · Cited by 114
The glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 114
Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents
Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
Xiao, Q., Boushey, R. P., Cino, M., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.4.r1057 · Cited by 111
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koška, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 115
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
van Poppel, P. C. M., Netea, M. G., Smits, P., & Tack, C. J. (2011) · Diabetes Care · doi:10.2337/dc10-2421 · Cited by 112
Kinetic study of the processing by dipeptidyl‐peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion
Lambeir, A., Durinx, C., Proost, P., Damme, J. V., Scharpé, S., & Meester, I. D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02982-9 · Cited by 112
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
Burkey, B. F., Hoffmann, P. K., Hassiepen, U., Trappe, J., Juedes, M. J., & Foley, J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00860.x · Cited by 111
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 108
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 112
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
Parkes, D. G., Mace, K. F., & TRAUTMANN, M. E. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 114

Authors: Kieffer, T. J., McIntosh, C. H., & Pederson, R. A.
Affiliations: University of British Columbia (CA)
ORCID: Kieffer, T J
Venue: Endocrinology
Publisher: The Endocrine Society
Published: 1995-08
Volume: 136
Issue: 8
Pages: 3585-3596
ISSN: 0013-7227 (ISSN-L)
1945-7170
DOI: 10.1210/endo.136.8.7628397
OpenAlex: W1978953702
Cited by: 1,124
References: 36
Citations by year: 2026: 9 · 2025: 31 · 2024: 30 · 2023: 15 · 2022: 27 · 2021: 36 · 2020: 23 · 2019: 37 · 2018: 25 · 2017: 40 · 2016: 39 · 2015: 54 · 2014: 47 · 2013: 53 · 2012: 61
FWCI: 6.60
Type: journal article
Language: en
Open access: closed
Locations: Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dipeptidyl peptidase IV, hormone degradation, incretin effect, N-terminal truncation, diprotin A, radiolabeled peptides, insulin secretion, circulating hormone levels
MeSH terms: Animals, Blood Physiological Phenomena, Glucagon-Like Peptides, Glucagon, Glucose, Peptide Fragments, Peptides, Protein Precursors, Rats, Inbred F344, Rats, Wistar, Dipeptidyl Peptidase 4, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks